The role of HCV proteins on treatment outcomes
© 2015 Kumthip and Maneekarn. For many years, the standard of treatment for hepatitis C virus (HCV) infection was a combination of pegylated interferon alpha (Peg-IFN-α) and ribavirin for 24-48 weeks. This treatment regimen results in a sustained virologic response (SVR) rate in about 50 % of cases....
Saved in:
Main Authors: | , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84949942482&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43972 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-43972 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-439722018-04-25T07:44:15Z The role of HCV proteins on treatment outcomes Kattareeya Kumthip Niwat Maneekarn Agricultural and Biological Sciences © 2015 Kumthip and Maneekarn. For many years, the standard of treatment for hepatitis C virus (HCV) infection was a combination of pegylated interferon alpha (Peg-IFN-α) and ribavirin for 24-48 weeks. This treatment regimen results in a sustained virologic response (SVR) rate in about 50 % of cases. The failure of IFN-α-based therapy to eliminate HCV is a result of multiple factors including a suboptimal treatment regimen, severity of HCV-related diseases, host factors and viral factors. In recent years, advances in HCV cell culture have contributed to a better understanding of the viral life cycle, which has led to the development of a number of direct-acting antiviral agents (DAAs) that target specific key components of viral replication, such as HCV NS3/4A, HCV NS5A, and HCV NS5B proteins. To date, several new drugs have been approved for the treatment of HCV infection. Application of DAAs with IFN-based or IFN-free regimens has increased the SVR rate up to > 90 % and has allowed treatment duration to be shortened to 12-24 weeks. The impact of HCV proteins in response to IFN-based and IFN-free therapies has been described in many reports. This review summarizes and updates knowledge on molecular mechanisms of HCV proteins involved in anti-IFN activity as well as examining amino acid variations and mutations in several regions of HCV proteins associated with the response to IFN-based therapy and pattern of resistance associated amino acid variants (RAV) to antiviral agents. 2018-01-24T04:36:37Z 2018-01-24T04:36:37Z 2015-12-15 Journal 1743422X 2-s2.0-84949942482 10.1186/s12985-015-0450-x https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84949942482&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43972 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Agricultural and Biological Sciences |
spellingShingle |
Agricultural and Biological Sciences Kattareeya Kumthip Niwat Maneekarn The role of HCV proteins on treatment outcomes |
description |
© 2015 Kumthip and Maneekarn. For many years, the standard of treatment for hepatitis C virus (HCV) infection was a combination of pegylated interferon alpha (Peg-IFN-α) and ribavirin for 24-48 weeks. This treatment regimen results in a sustained virologic response (SVR) rate in about 50 % of cases. The failure of IFN-α-based therapy to eliminate HCV is a result of multiple factors including a suboptimal treatment regimen, severity of HCV-related diseases, host factors and viral factors. In recent years, advances in HCV cell culture have contributed to a better understanding of the viral life cycle, which has led to the development of a number of direct-acting antiviral agents (DAAs) that target specific key components of viral replication, such as HCV NS3/4A, HCV NS5A, and HCV NS5B proteins. To date, several new drugs have been approved for the treatment of HCV infection. Application of DAAs with IFN-based or IFN-free regimens has increased the SVR rate up to > 90 % and has allowed treatment duration to be shortened to 12-24 weeks. The impact of HCV proteins in response to IFN-based and IFN-free therapies has been described in many reports. This review summarizes and updates knowledge on molecular mechanisms of HCV proteins involved in anti-IFN activity as well as examining amino acid variations and mutations in several regions of HCV proteins associated with the response to IFN-based therapy and pattern of resistance associated amino acid variants (RAV) to antiviral agents. |
format |
Journal |
author |
Kattareeya Kumthip Niwat Maneekarn |
author_facet |
Kattareeya Kumthip Niwat Maneekarn |
author_sort |
Kattareeya Kumthip |
title |
The role of HCV proteins on treatment outcomes |
title_short |
The role of HCV proteins on treatment outcomes |
title_full |
The role of HCV proteins on treatment outcomes |
title_fullStr |
The role of HCV proteins on treatment outcomes |
title_full_unstemmed |
The role of HCV proteins on treatment outcomes |
title_sort |
role of hcv proteins on treatment outcomes |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84949942482&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43972 |
_version_ |
1681422472887402496 |